देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
BICALUTAMIDE
MYLAN PHARMACEUTICALS ULC
L02BB03
BICALUTAMIDE
50MG
TABLET
BICALUTAMIDE 50MG
ORAL
30/100
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0127996001; AHFS:
CANCELLED POST MARKET
2017-01-09
PRODUCT MONOGRAPH MYLAN-BICALUTAMIDE Bicalutamide Tablets 50 mg Non-Steroidal Antiandrogen Mylan Pharmaceuticals ULC 85 Advance Rd. Etobicoke, ON M8Z 2S6 Submission Control No.: 194537 Date of Revision: May 13, 2016 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 3 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 8 DRUG INTERACTIONS ................................................................................................. 12 DOSAGE AND ADMINISTRATION ............................................................................. 13 OVERDOSAGE ............................................................................................................... 13 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 14 STORAGE AND STABILITY ......................................................................................... 15 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 15 PART II: SCIENTIFIC INFORMATION .............................................................................. 16 PHARMACEUTICAL INFORMATION ......................................................................... 16 CLINICAL TRIALS ......................................................................................................... 16 DETAILED PHARMACOLOGY .................................................................................... 20 TOXICOLOGY ......................................... पूरा दस्तावेज़ पढ़ें